Poor angioplasty sales drag down Pfizer's results
This article was originally published in Clinica
Executive Summary
Declining sales of Pfizer's angioplasty and urology products led to flat growth in the company's medical technology sector, where sales rose only 1% to $1.5 billion in 1997. The company attributes this to pricing pressures and new product competition.